Clarity Pharmaceuticals Reports Positive Interim Results from Prostate Cancer Trial

Clarity Pharmaceuticals announced encouraging interim results from its SECuRE Phase I/IIa trial for 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The update includes strong PSA response rates, with 74% of participants achieving a PSA25 response, and two additional complete responses observed at a higher dose level. These findings suggest potential efficacy for patients with advanced disease who have undergone multiple prior therapies.